Nymox Pharmaceutical Corporation (NYMX): Price and Financial Metrics
GET POWR RATINGS... FREE!
NYMX Stock Summary
- With a price/sales ratio of 19,802.13, Nymox Pharmaceutical Corp has a higher such ratio than 99.91% of stocks in our set.
- With a year-over-year growth in debt of 189.8%, Nymox Pharmaceutical Corp's debt growth rate surpasses 94.24% of about US stocks.
- Revenue growth over the past 12 months for Nymox Pharmaceutical Corp comes in at -97.77%, a number that bests only 0.87% of the US stocks we're tracking.
- Stocks that are quantitatively similar to NYMX, based on their financial statements, market capitalization, and price volatility, are URG, CALT, MRSN, FSR, and EQS.
- NYMX's SEC filings can be seen here. And to visit Nymox Pharmaceutical Corp's official web site, go to www.nymox.com.
NYMX Valuation Summary
- In comparison to the median Healthcare stock, NYMX's price/earnings ratio is 138.9% lower, now standing at -14.2.
- Over the past 243 months, NYMX's EV/EBIT ratio has gone up 8.9.
- NYMX's price/sales ratio has moved up 32812.5 over the prior 243 months.
Below are key valuation metrics over time for NYMX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NYMX | 2021-08-31 | 33220 | 77.4 | -14.2 | -13.9 |
| NYMX | 2021-08-30 | 33680 | 78.5 | -14.3 | -14.1 |
| NYMX | 2021-08-27 | 34140 | 79.6 | -14.5 | -14.3 |
| NYMX | 2021-08-26 | 33220 | 77.4 | -14.2 | -13.9 |
| NYMX | 2021-08-25 | 33520 | 78.1 | -14.3 | -14.1 |
| NYMX | 2021-08-24 | 32120 | 74.9 | -13.7 | -13.5 |
NYMX Growth Metrics
- The 5 year cash and equivalents growth rate now stands at 261.2%.
- Its 4 year revenue growth rate is now at -58.88%.
- Its 3 year cash and equivalents growth rate is now at 1258.76%.
The table below shows NYMX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 0 | -9.255 | -11.754 |
| 2021-06-30 | 0 | -10.275 | -12.612 |
| 2021-03-31 | 0 | -10.537 | -11.562 |
| 2020-12-31 | 0.005 | -10.037 | -11.738 |
| 2020-09-30 | 0.031 | -10.166 | -12.398 |
| 2020-06-30 | 0.07 | -8.038 | -10.703 |
NYMX Stock Price Chart Interactive Chart >
NYMX Price/Volume Stats
| Current price | $1.26 | 52-week high | $2.27 |
| Prev. close | $1.25 | 52-week low | $0.94 |
| Day low | $1.22 | Volume | 40,900 |
| Day high | $1.27 | Avg. volume | 178,734 |
| 50-day MA | $1.36 | Dividend yield | N/A |
| 200-day MA | $1.60 | Market Cap | 113.75M |
Nymox Pharmaceutical Corporation (NYMX) Company Bio
Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimers disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company was founded in 1989 and is based in Nassau, The Bahamas.
Latest NYMX News From Around the Web
Below are the latest news stories about Nymox Pharmaceutical Corp that investors may wish to consider to help them evaluate NYMX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back to a new year, investor! |
What You Need To Know About Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) Investor CompositionA look at the shareholders of Nymox Pharmaceutical Corporation ( NASDAQ:NYMX ) can tell us which group is most... |
Nymox Shareholder UpdateHASBROUCK HEIGHTS, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the Company) is pleased to announce that it has completed all the Companys required tasks in preparation for its planned upcoming regulatory submission for Fexapotide Triflutate for the treatment of BPH. |
State Street Corp Has $48,000 Position in Nymox Pharmaceutical Co. (NASDAQ:NYMX)State Street Corp cut its position in Nymox Pharmaceutical Co. (NASDAQ:NYMX) by 95.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,494 shares of the biopharmaceutical companys stock after selling 624,899 shares during the period. State Street Corps holdings in Nymox Pharmaceutical were worth [] The post State Street Corp Has $48,000 Position in Nymox Pharmaceutical Co. (NASDAQ:NYMX) appeared first on ETF Daily News . |
Head-To-Head Survey: Nymox Pharmaceutical (NYMX) vs. The CompetitionNymox Pharmaceutical (NASDAQ: NYMX) is one of 38 public companies in the Diagnostic substances industry, but how does it weigh in compared to its competitors? We will compare Nymox Pharmaceutical to related companies based on the strength of its valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and risk. Analyst Recommendations This is a summary [] |
NYMX Price Returns
| 1-mo | -10.64% |
| 3-mo | -8.70% |
| 6-mo | -13.70% |
| 1-year | -24.55% |
| 3-year | -25.00% |
| 5-year | -66.13% |
| YTD | -3.08% |
| 2021 | -47.58% |
| 2020 | 12.73% |
| 2019 | 67.94% |
| 2018 | -60.30% |
| 2017 | 23.60% |
Continue Researching NYMX
Here are a few links from around the web to help you further your research on Nymox Pharmaceutical Corp's stock as an investment opportunity:Nymox Pharmaceutical Corp (NYMX) Stock Price | Nasdaq
Nymox Pharmaceutical Corp (NYMX) Stock Quote, History and News - Yahoo Finance
Nymox Pharmaceutical Corp (NYMX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...